在帕金森病的认知和胆固醇系统轨迹
medRxiv : the preprint server for health sciences
|July 29, 2024
概括
在大脑后部区域减少的[18F]-FEOBV结合预测了帕金森病 (PD) 的认知衰退. 升级的胆固醇系统可以补偿轻度至中度PD的认知变化.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射化学 放射化学是指辐射化学.
背景情况:
- 认知能力下降是帕金森病 (PD) 的一个显著的非运动症状.
- 胆固醇系统退化与PD相关的认知障碍有关.
- 之前的研究主要使用横截面设计来检查这种关联.
研究的目的:
- 调查基线囊泡性乙胆载体 (VAChT) 结合是否预测非痴呆PD患者的纵向认知变化.
- 在两年内探索[18F]-FEOBV结合模式和认知轨迹之间的关系.
- 阐明胆固醇系统在PD认知变异中的作用.
主要方法:
- 75名轻度至中度,非痴呆PD患者接受了基线认知评估和[18F]-FEOBVPET成像.
- 经过两年,认知功能被重新评估,将参与者分为四个认知组.
- 在[18F]-FEOBV结合和认知变化之间进行了全脑素比较和相关性分析.
主要成果:
- 在所有认知类别中观察到明显的基线[18F]-FEOBV结合模式.
- 在持续正常认知和MCI逆转组中,前部区域的结合增加.
- 减少后皮层,边缘和准边缘[18F]-FEOBV结合在两年内预测了全球和特定领域的认知衰退.
结论:
- 通过[18F]-FEOBV结合测量胆固醇系统完整性,与PD的认知轨迹相关.
- 胆固醇神经传递的升调可能是轻度至中度PD的补偿机制.
- 基线VAChT结合是PD未来认知衰退的重要预测因素.
相关概念视频
01:15Parkinson's Disease: Overview
510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:24Cholinergic Antagonists: Pharmacokinetics
426
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
426